Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswireDec 13 21:30

H.C. Wainwright Maintains Medicenna Therapeutics(MDNAF.US) With Buy Rating, Maintains Target Price $2.5

Futu NewsDec 7 02:31 · Ratings

Updated MDNA11 Monotherapy and Combination Clinical Data From the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference

GlobeNewswireNov 27 20:00

Medicenna Therapeutics GAAP EPS of -C$0.05

Seeking AlphaNov 15 23:55

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswireNov 13 20:00

Medicenna Announces Positive Single-Agent Activity of MDNA11 From Dose Expansion Cohort and Encouraging Safety Profile in Combination With KEYTRUDA (Pembrolizumab) at the 39th Annual Meeting of SITC

GlobeNewswireNov 11 20:00